Why LeMaitre Vascular Is A Market Leader In Core Segments: Oppenheimer Initiates With Outperform Rating
Portfolio Pulse from Vandana Singh
Oppenheimer has initiated coverage on LeMaitre Vascular Inc (NASDAQ:LMAT) with an Outperform rating and a price target of $70. The company generates 90% of its sales from a third of its core markets, and its products are used by 11,000 vascular surgeons from 4,800 hospitals. LMAT's growth strategy includes smaller strategic acquisitions, with a successful track record of securing 70% of their 24 acquisition endeavors over the past 20 years.
September 06, 2023 | 7:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
LeMaitre Vascular Inc (NASDAQ:LMAT) has been given an Outperform rating by Oppenheimer, with a price target of $70. The company's strategic acquisitions and widespread product adoption contribute to its market leadership.
The Outperform rating from Oppenheimer indicates a positive outlook for LMAT. The company's successful strategy of smaller strategic acquisitions and widespread product adoption contribute to its market leadership, which is likely to positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100